Prevalence of *Plasmodium falciparum* antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014

Dominique Fatima Voumbo-Matoumona1,2,3
Lady Charlène Kouna4
Marylin Madamet2,5,6
Sydney Maghendji-Nzondo4
Bruno Pradines2,5,6
Jean Bernard Lekana-Douki1,4

1Unit of Evolution, Epidemiology and Parasitic Resistances (UNEEREP), International Medical Research Center of Franceville (CIRMF), Franceville, Gabon; 2Parasitology and Entomology Unit, Department of Infectious Diseases, Biomedical Research Institute of Army, Marseille, France; 3Regional Doctoral School of Central Africa in Tropical Infectiology, Franceville, Gabon; 4Department of Parasitology, Mycology and Tropical Medicine, University of Health Sciences, Libreville, Gabon; 5Research Unit on Infectious and Tropical Emerging Diseases, Aix Marseille University, Marseille, France; 6National Malaria Reference Center, Marseille, France

**Purpose:** The introduction of artemisinin-based combination therapies (ACTs) in treating uncomplicated malaria and sulfadoxine–pyrimethamine (SP) as intermittent preventive treatment during pregnancy drastically decreased the burden of malarial disease around the world. However, ACTs are known to select for drug resistance markers. In Gabon, artemether–lumefantrine induced an increase in the prevalence of N86-Pfdmrd1, which is associated with treatment failure. However, little data are available regarding resistance markers in Southeastern Gabon. This study aimed to evaluate the evolution of resistance haplotypes in the *Pfcr*, *Pfdhps*, *Pfdhfr*, and *PfK13* genes from 2011 to 2014 in Southeastern Gabon.

**Methods:** A total of 233 *Plasmodium falciparum* DNA samples were collected from febrile pediatric patients in South Gabon: Franceville, an urban area; Koulamoutou, a semi-urban area; and Lastourville, a rural area. *Pfcr*, *Pfdhps*, *Pfdhfr*, and the propeller domain of *PfK13* were sequenced for all isolates.

**Results:** The overall prevalence (3.7%–11.5%) of the wild-type haplotype *Pfcr* 72-76 CVMNK was not significantly different between 2011 and 2014 in Southeast Gabon. For *Pfdhfr* (codons 51, 59, 108, 164), the IRNI triple-mutant haplotype was the most prevalent (>89.0%). The ICNI and NCNI mutant haplotypes and the NCSI wild-type haplotype showed a minor prevalence. There were no differences in the distributions of these haplotypes across the 4 years and the three study sites. For *Pfdhps*, the AAKAA and SGKAA mutant haplotypes and the SAKAA wild-type haplotype were similarly present in the three areas during the study period. The AGKAA double mutant was first observed in 2013 in Franceville and in 2014 in Koulamoutou and Lastourville. Interestingly, only the A578S mutation (0.4%) and two new A494V (0.4%) and V504A (0.9%) mutations were found in *PfK13*.

**Conclusion:** Despite the withdrawal of chloroquine, the frequency of the resistant allele 76T remained high in the south of Gabon. Moreover, a high level of resistant haplotypes against IPTp-SP was found.

**Keywords:** *Plasmodium falciparum*, antimalarial drug resistance, *Pfdhfr/Pfdhps*, *Pfcr*, *PfK13*, Gabon

**Introduction**

Malaria is the most important parasitic disease in the world and affects children and pregnant women in particular. Africa has the most substantial burden, especially sub-Saharan African countries, with ~216 million cases of illness and 445,000 deaths in 2016.1 The emergence of drug resistance remains a major obstacle in the fight against malaria. Given the spread of resistance to the major antimalarial drugs, the World Health Organization (WHO) has recommended the use of artemisinin-based combination therapies (ACTs) to
treat uncomplicated malaria and sulfadoxine–pyrimethamine (SP) as an intermittent preventive treatment during pregnancy (IPTp). Consequently, since 2010, the mortality rates due to malaria have fallen by 32%.1 However, the emergence of artemisinin resistance, manifested by delayed parasite clearance after monotherapy with artesunate or ACTs, was described in Southeast Asia.2,3 The withdrawal of previous antimalarial drugs and the switch to ACTs were followed in some countries by a reemergence of some wild-type alleles that were associated with susceptibility to the previous drug treatment. This was reported for the Pfcrte chloroquine marker (Plasmodium falciparum chloroquine resistance transporter) in Tanzania. The K76 wild-type haplotype increased after abandoning chloroquine use and implementing artemether–lumefantrine treatment.4

Two genes, Pfdrfr (P. falciparum dihydrofolate reductase) and Pfdrps (P. falciparum dihydropteroate synthase), have been associated with pyrimethamine and sulfadoxine resistance, respectively, around the world.5 The triple Pfdrfr mutation N51I, C59R, and S108N increased from 92.9% to 100% and from 17.9% to 75.6%, respectively, between 2005 and 2011 in pregnant women.6 The frequencies of Pfdrfr triple and quintuple mutants (Pfdrps A437G) increased from 92.9% to 100% and from 17.9% to 75.6%, respectively, between 2005 and 2011 in pregnant women treated after IPTp with SP.7 A recent exploration of PfK13 at Libreville did not detect any mutation.8 There are no available data on the prevalence of PfK13 mutations in South Gabon.

The aim of this retrospective study was to determine the evolution of the prevalence of wild-type/mutant haplotypes for different genes linked to resistance, such as Pfcrte (codons 72 to 76), Pfdrfr (51, 59, 108, 164), Pfdrps (436, 437, 540, 581, 613), and PfK13 between 2011 and 2014 in Lastourville, Koulamoutou, and Franceville, three cities located in Southeast Gabon.

**Methods**

**Study sites**

The present study was approved by the Gabonese National Ethics Committee (no 0023/2013/SG/CNE). Parents or guardians gave their written informed consent before collection of blood samples. This study was conducted in three cities located in Southeast Gabon: Franceville, an urban area, from 2011 to 2014; Koulamoutou, a semi-urban area, from 2013 to 2014; and Lastourville, a rural area, from 2013 to 2014 (Figure 1). The transverse collection of peripheral and venous blood in children under 15 years of age was performed.

**Diagnosis and DNA extraction**

Plasmodial infection was diagnosed using thin blood smears according to Lambarene’s method.11 DNA extraction was done from archived whole blood using the DNA Blood Omega Bio-tek E.Z.N.A® method (Omega Bio-tek, Norcross, GA, USA) according to the manufacturer’s protocol as previously described.12

**Antimalarial resistance gene single-nucleotide polymorphisms (SNPs)**

The Pfcrte, Pfdrfr, and Pfdrps genes were amplified by polymerase chain reaction (PCR) using the primers listed in Table 1.
The reaction mixture and programs for the thermal cycler were done as previously described. Briefly, the reaction mixture consisted of Red Diamond Taq DNA buffer (50 mM KCl, 10 mM Tris, pH 8.3), 200 µM deoxynucleotide triphosphate (dNTP), ~200 ng of genomic DNA, 0.32 µM forward and reverse primers, and 0.3 U of Red Diamond Taq DNA polymerase in a final volume of 50 µL. The concentration of MgCl₂ was 2.5 mM for Pf dhfr, Pf dhps, and Pf K13 (primary PCR), 4.5 mM for Pfcrt and 5 mM for Pf K13 (nested PCR).

The thermal cycler was programmed differently depending on the gene to be amplified as described previously.

The Pf K13 propeller gene was amplified using a PCR and nested PCR method as described previously. Primer sequences and hybridization temperatures are shown in Table 1.

The amplicons were sequenced according to the Sanger sequencing method using 4 µL of BigDye Terminator® v3.1 mix (Life Technologies, Carlsbad, CA, USA) and 0.8 µM...
of the primers described in Table 1 in a 20 µL volume. The cycle conditions were an initial denaturation at 96°C for 5 min, followed by 30 cycles at 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. Excess dye terminators were removed with a BigDyeXTerminator® Purification Kit (Life Technologies). The samples were loaded on an ABI Prism 3100 analyzer (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturers’ instructions. The sequences were analyzed using the Vector NTI advanced (TM) software (version 11; Thermo Fisher Scientific) to identify specific SNP combinations.

Statistical methods

All data were recorded in Excel (Office 2013). Statistical analysis was carried out with the R software version 3.2.1. Age was expressed as the median and interquartile range (IQR), and parasite densities were expressed as the geometric means (GMPD). The chi-square test was used to compare the categorical variables among the groups. The nonparametric Kruskal–Wallis test and Fisher’s exact test were used for group comparisons, as appropriate. Significance was assumed at \( p < 0.05 \).

Results

Parasitemia of \( \text{P. falciparum} \) infected samples

A total of 233 samples infected by \( \text{P. falciparum} \) were collected from 2011 to 2014 in Franceville, Koulamoutou, and Lastourville (Table 2). There was a significant difference in the comparison of parasitemia among the three localities in 2013. The parasitemia was higher in Franceville and Lastourville (17,022 and 17,754 parasites/µL, respectively) than it was in Koulamoutou (2,905 parasites/µL, respectively) in 2014. The parasitemia was highest in Lastourville (16,586 parasites/µL), followed by Franceville (8,878 parasites/µL) and Koulamoutou (2,192 parasites/µL) \( (p=0.004) \). A significant difference was found in the mean ages of the children from the three cities in 2013 and 2014 (Table 2). In 2013, the mean age was highest in Franceville (79 months), followed by Koulamoutou (42 months) and Lastourville (36 months) \( (p=0.0005) \). In 2014, the children from Franceville (66 months) and Koulamoutou (50 months) were older than those from Lastourville (36 months) \( (p=0.007) \). However, no difference was observed between Franceville and Koulamoutou \( (p=0.59) \). Furthermore, no difference was found in each site during the study period \( (p>0.05) \).

\( \text{P. falciparum} \) antimalarial resistance genes \( \text{Pfcrt} \)

At least 89.5% of the isolates presented only one \( \text{Pfcrt} \) polymorphism. CVIET was the main haplotype, and its overall prevalence was stable during the study period: 88.2% \( (n=15) \), 96.3% \( (n=24) \), 84.7% \( (n=61) \), and 88.5% \( (n=54) \) from 2011 to 2014, respectively, at the three sites. The overall prevalence of CVMNK, which is associated with chloroquine susceptibility, was also not significantly different over the years: 5.9% \( (n=1) \) in 2011, 3.7% \( (n=1) \) in 2012, 9.7% \( (n=7) \) in 2013, and 11.5% \( (n=7) \) in 2014. Mixed genotypes were found only in 2011 (5.9%, \( n=1 \)) at Franceville and 2013 in all sites (5.4%, \( n=4 \)).

At Franceville, an increase in the frequency of the CVMNK haplotype was found between 2012 \( (n=1, 4.0\%) \) and 2014 \( (n=5, 29.4\%) \) \( (p=0.03) \) (Table 3). However, the

**Table 2 Characteristics of study samples**

<table>
<thead>
<tr>
<th>Study sites</th>
<th>Character</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franceville</td>
<td>No of subjects</td>
<td>29</td>
<td>30</td>
<td>27</td>
<td>28</td>
<td>0.49</td>
</tr>
<tr>
<td></td>
<td>Sex ratio (M/F)</td>
<td>1.9</td>
<td>1.14</td>
<td>0.92</td>
<td>0.59</td>
<td>0.29</td>
</tr>
<tr>
<td></td>
<td>Mean age</td>
<td>53.39 (6–154)</td>
<td>58.20 (13–166)</td>
<td>78.96 (41–168)</td>
<td>66.20 (24–156)</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>Geometric parasitemia</td>
<td>7,068.68 (350–147,500)</td>
<td>9,982.81 (100–200,000)</td>
<td>17,022.40 (1,750–453,600)</td>
<td>8,878.64 (420–369,600)</td>
<td>0.29</td>
</tr>
<tr>
<td>Koulamoutou</td>
<td>No of subjects</td>
<td>29</td>
<td>30</td>
<td>28</td>
<td>30</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>Sex ratio (M/F)</td>
<td>0.93</td>
<td>1.5</td>
<td></td>
<td></td>
<td>0.75</td>
</tr>
<tr>
<td></td>
<td>Mean age</td>
<td>41.87 (8–168)</td>
<td>50.19 (5–156)</td>
<td>66.20 (24–156)</td>
<td>0.59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Geometric parasitemia</td>
<td>2,905.12 (72–31,320)</td>
<td>2,192.31 (72–37,440)</td>
<td>2,192.31 (72–37,440)</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>Lastourville</td>
<td>No of subjects</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td>Sex ratio (M/F)</td>
<td>1.73</td>
<td>1.14</td>
<td></td>
<td></td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Mean age</td>
<td>36.07 (12–108)</td>
<td>36.23 (10–156)</td>
<td>36.23 (10–156)</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Geometric parasitemia</td>
<td>17,754.41 (105–425,600)</td>
<td>16,586.84 (1,260–285,600)</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Geometric means of age (months) with interquartile ranges; geometric means of parasitemia (parasites/µL) with interquartile ranges.

**Abbreviations:** F, female; M, male.
number of parasites with CVMNK haplotype was too low to conclude that there was a reemergence of chloroquine-susceptible strains. In 2014, the CVMNK frequency in Franceville (n=5, 29.4%) was significantly higher than that in Lastourville (n=1, 5.9%) and Koulamoutou (n=1, 3.7%) (p<0.04). However, there was no significant difference in the frequencies of this haplotype in the other years (p>0.05).

**Pfdhfr**

The analysis of *Pfdhfr* sequences showed that there were no mixed genotypes in all the isolates, except in one from Franceville in 2014. Only two isolates from Lastourville, one collected in 2013 and one in 2014, harbored the wild-type NCSI haplotype for codons 51, 59, 108, and 164. The prevalence of the IRNI (N51I, C59R, S108N) triple mutants that were associated with pyrimethamine resistance remained high in the three sites. Its overall prevalence was 100% (n=20) for 2011, 2013, and 2014, respectively. No 540E and 581G mutations were observed, and only one isolate from Koulamoutou in 2014 carried the A613S mutation.

There was no significant difference in the frequency of each haplotype between the study sites and the years (p≥0.05) (Table 4).

**Pfdhps**

The overall prevalence of the quadruple mutant (*Pfdhps* [437] and *Pfdhfr* [51+59+108]) was 100% (n=3), 80.4% (n=51), and 92.9% (n=28) for 2011, 2013 and 2014, respectively, with no significant increase between 2013 and 2014 (p=1). In each site, the distribution of the quadruple mutant (*Pfdhps* [436/437] and *Pfdhfr* [51+59+108]) was not significantly different during the study period at Franceville (p=0.32), Koulamoutou (p=0.32), and Lastourville (p=0.32) (Table 4).

No quintuple (*Pfdhps* [437+540] and *Pfdhfr* [51+59+108]) or sextuple (*Pfdhps* [437+540+581] and *Pfdhfr* [51+59+108]) mutants were observed.

**Pfk13**

The propeller domain of the *Pfk13* gene did not show a great diversity of alleles. Of the 233 sequenced isolates, only four carried one of the non-synonymous mutations as follows: A578S (n=1, 0.4%), A504V (n=1, 0.4%), V494A (n=2, 0.9%). Three isolates collected in 2011 in Franceville harbored the A578S, A504V, or V494A mutation. One isolate collected in 2013 in Koulamoutou carried the V494A mutation.

**Discussion**

To investigate the evolution of antimalarial drug resistance, children younger than 6 and 168 months, with a mean age between 36 and 79 months, were identified at the three sites. We retrospectively analyzed samples from 2011 to 2014, but the data were only from 2013 to 2014 for Lastourville and Koulamoutou.

### Table 3 Prevalence of Pfcrt haplotypes

<table>
<thead>
<tr>
<th>Study sites</th>
<th>Year</th>
<th>CVMNK (%)</th>
<th>CVIET (%)</th>
<th>Multiple clones (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franceville</td>
<td>2011 (n=17)</td>
<td>5.9</td>
<td>88.2</td>
<td>5.9</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>2012 (n=25)</td>
<td>3.7</td>
<td>96.3</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2013 (n=19)</td>
<td>10.5</td>
<td>78.9</td>
<td>10.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2014 (n=17)</td>
<td>29.4</td>
<td>70.6</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>Koulamoutou</td>
<td>2013 (n=25)</td>
<td>12.0</td>
<td>84.0</td>
<td>4.0</td>
<td>0.22</td>
</tr>
<tr>
<td></td>
<td>2014 (n=28)</td>
<td>3.7</td>
<td>96.3</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>Lastourville</td>
<td>2013 (n=28)</td>
<td>7.1</td>
<td>89.3</td>
<td>3.6</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2014 (n=17)</td>
<td>5.9</td>
<td>94.1</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>All sites</td>
<td>2013 (N=72)</td>
<td>9.7</td>
<td>84.7</td>
<td>5.9</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>2014 (N=62)</td>
<td>11.5</td>
<td>88.5</td>
<td>0.0</td>
<td></td>
</tr>
</tbody>
</table>
There was a significant difference in the mean age between 2013 and 2014 at the three sites. The children enrolled in Lastourville and Koulamoutou (rural and semi-urban areas, respectively) were younger than those from the urban site of Franceville. This was consistent with previous studies, which reported the association of an increase of the mean age of *P. falciparum*-infected children with the drop of malaria prevalence in urban localities, such as Franceville, and in other endemic areas, such as Gambia. This increase is due to the delay of immunity acquisition. Indeed, the decrease in the malaria burden has led to a decrease in the number of infective bites, which consequently limits immune stimulation. It was previously shown that the malaria prevalence was higher in Lastourville than in Franceville and Koulamoutou, leading to a higher antimalarial immunity in Lastourville than in Franceville and Koulamoutou. Indeed, parasitemia was higher in the rural site in 2013 and 2014. A probable hypothesis is the better availability of antimalarial treatment and preventive measures in urban areas. These findings can also be associated with the prevalence of other parasitic or infectious diseases in rural areas that increased the anti-infectious disease immunity, as previously reported.

*P. falciparum* drug resistance remains a challenge for controlling the malarial burden. The analysis of *Pfcrt* (chloroquine resistance marker) revealed a significant increase in the chloroquine-susceptible wild-type haplotype CVMNK between 2012 and 2014 in Franceville (the urban area), despite a high level of the resistant haplotype CVIET. However, although the results were significant, these data were determined in a small number of samples (1/17 in 2011, 1/25 in 2012, 2/19 in 2013, and 5/17 in 2014), suggesting an absence of a noticeable reemergence of strains susceptible to chloroquine. The prevalence of resistant strains to chloroquine was still 70.6%. In the semi-urban and rural sites, no significant difference was observed, and the prevalence of the resistant haplotype CVIET remained high since 2000. Despite the implementation of ACT and the withdrawal of chloroquine, the frequency of the resistant allele 76T remained high in Franceville (93.8% in 2004, 96% in 2009, and from 70.6% to 96.3% between 2011 and 2014) and in all of Gabon (100% from 1995 until 2002, 97% from 2005 until 2007, and above 70% since 2008). Recent studies conducted in Gabon from 1995 to 2008 showed an increased but non-significant amount of the wild-type allele K76, as shown in other studies in Sub-Saharan Africa. In South Gabon, the frequency of the resistant allele 76T was higher at 2009. There can be a long delay in the selection of the T76 *Pfcrt* genotype, as shown in previous data from

<table>
<thead>
<tr>
<th>Study sites</th>
<th>Years</th>
<th>N</th>
<th>IRNI (%)</th>
<th>NCNI (%)</th>
<th>NCSI (%)</th>
<th>NCNI (%)</th>
<th>51+/IRNI (%)</th>
<th>59+/IRNI (%)</th>
<th>108+/IRNI (%)</th>
<th>51+/59+/IRNI (%)</th>
<th>51+/59+/108+/IRNI (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franceville</td>
<td>2011</td>
<td>15</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td></td>
<td>2012</td>
<td>23</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td></td>
<td>2013</td>
<td>22</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td></td>
<td>2014</td>
<td>19</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td>Koulamoutou</td>
<td>2013</td>
<td>26</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td></td>
<td>2014</td>
<td>29</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td>Lastourville</td>
<td>2013</td>
<td>29</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td></td>
<td>2014</td>
<td>17</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
<tr>
<td>All sites</td>
<td>2013</td>
<td>62</td>
<td>0.0</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>100.0</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Note: Quadruple mutations = *Pfcrt* (51+/59+/108+).
Zanzibar, where this selection was not observed in 2005 but clearly appeared in 2009.44,48 Indeed, recent data from Franceville showed a significant decrease of T76 prevalence around 10 years after chloroquine withdrawal.37 These findings suggest that the selection of T76 Pfcrt takes more time after changes in the antimalarial policy. So, some explanations of the non-significant variation of T76 prevalence between 2011 and 2014 could be the short time and also the smallness of the study effectives here. Furthermore, the T76 prevalence found at 2014 was similar to the previous findings.37 The high frequency of the resistant allele 76T in the South of Gabon may also be due to cross resistance with amodiaquine used in combination with artesunate despite the withdrawal of chloroquine.49-51. On other hand, some reports highlighted that an increase in chloroquine resistance has been observed in recent years following a decrease due to the withdrawal of chloroquine and the introduction of ACT in 2002 in Senegal.

Because of the implementation of IPTp with SP, the Pf
dhfr and Pf
dhps haplotypes associated with SP resistance were investigated. According to published data from Gabon, the most frequent Pf
dhfr haplotype found was the triple-mutant IRNI, which is present in the three localities. A previous study showed that IRNI was the most prevalent Pf
dhfr haplotype found both in Librevene (>92%) in 2007 in Northwest Gabon and in Libreville in 2011 in pregnant women after IPTp with SP (100%).24,29,30,52 These high prevalences of IRNI (>90%) were also observed in Central Africa.53-55 The withdrawal of IPT with SP induced the decline of the IRNI haplotype in North-western Ethiopia, suggesting that the high prevalence of IRNI is maintained due to the use of pyrimethamine.56

Among the successfully analyzed Pf
dhps sequence, only mutations at codons 436 and/or 437 have been observed in the three localities. The SGKAA haplotype bearing the 437 single mutation is predominant (50%-100%). These data were consistent with the selection of the 437G mutation reported recently between 2005 and 2008 in North Gabon.30 A non-significant increase in the haplotype with the double mutations 436 and/or 437 AGKAA has been observed since 2005 in Koulamoutou and Lastourville. No haplotype with the 540 and 581 mutations has been observed, contrary to other African countries, such as the Congo, which is a neighbor of Gabon.57 Indeed, the K540E mutation was found in Libreville between 2005 and 2006 and in Lambarene.24,29 However, previous data from the Haut Ogooué province did not report mutations in codons 540 and 581 in 2000.58 The K540E and A581G mutations contributed strongly to reducing the effectiveness of SP during pregnancy.57,58 The A613S mutation, which is rarely found in Africa, was present in only one isolate. No A613T mutations described in Asia and East Africa were found in our study.24,40,61

The high prevalence of the IRNI haplotype of Pf
dhfr and the SGKAA of Pf
dhps concomitantly in urban and rural areas suggested a similar level of adhesion of IPT with SP in urban and rural areas. The absence of high-grade resistance mutant haplotypes (Pf
dhfr [51+59+108] + Pf
dhps [437+540+581]) associated with IPTp-SP failures during pregnancy in the three localities suggests the efficiency of SP as IPTp.62 This efficiency was associated with a decrease in the prevalence of microscopic P. falciparum infection during pregnancy following IPTp-SP implementation in the urban cities of Gabon.63 However, the highest level of the triple Pf
dhfr mutant plus Pf
dhps 437 mutant, considered as marker for SP failure, call for the need of IPTp-SP efficacy monitoring.

Monitoring the emergence and spread of artemisinin resistance is a great challenge. However, the emergence of artemisinin resistance, as manifested by delayed parasite clearance after monotherapy with artesunate or ACT, was described in Southeast Asia.23 Several mutations in the PfK13 propeller gene and, more specifically, the C580Y, Y493H, R539T, and I543T mutations were associated with artemisinin resistance in Southeast Asia.2-9,11 None of the mutations described in Southeast Asia that were linked to artemisinin resistance were detected in our samples. The use of bitherapies in the treatment of malaria can delay the apparition of drug resistance. Also, the very short half-life of artemisinin is not favorable for the selection of resistant parasite. These two factors could explain the fact that, less than 10 years after ACT implementation, no molecular markers for artemisinin resistance was observed. Those results were consistent with previous studies in Africa.10,12-17,64 The A578S mutation was detected in one isolate (0.4%). This mutation was often reported in Africa but it had a low prevalence (<2%).10,12,17,20,22,23 This mutation was also identified in Bangladesh.65 However, A578S mutation was not associated with artemisinin treatment failure and all the patients carrying the mutant parasites were cured by artemether–lumefantrine or ASAQ before day 3.10,21 Furthermore, the absence of a role for the A578S mutation in artemisinin resistance was confirmed in an in vitro study using site-directed mutagenesis.18 Two others mutations, V494A (0.4%) and A504V (0.9%), were identified for the first time in two isolates. A non-synonymous mutation V494I was observed in Angola and in Mozambique but was not associated with artemisinin resistance.66 This study described new PfK13 polymorphisms, but the lack of
an in vitro assay did not allow us to determine the absence of resistance to artemisinin in the southeast of Gabon. However, the role of PfK13 polymorphisms in artemisinin derivatives in Africa is still debated. Recent publications reported that parasites collected from African patients who were still parasitemic at day 3 and beyond did not carry mutations in PfK13 after ACT treatment.67–70

**Conclusion**

This study showed a high prevalence of a Pfcrt-resistant haplotype in Gabon between 2011 and 2014 (>70%), even though chloroquine was no longer used. Despite a great diversity and variable distribution of the alleles linked to SP susceptibility, no resistant quintuple mutation haplotypes associated with IPTp-SP failure have been found in this period. Since ACT implementation, there is not yet artemisinin resistance in Southeast Gabon. However, the spread of antimalarial drug resistance from Southeast Asia to Africa, as described for chloroquine and SP, requires an intensive epidemiological survey.71,72

**Acknowledgments**

The authors thank the children and their parents who participated in the study and the staff of the pediatric wards of the health center laboratories of Lastourville, the regional hospitals, and Paul Moukambi and Amissa Bongo in Koulamoutou health center laboratories of Lastourville, the regional hospitals, and Paul Moukambi and Amissa Bongo in Koulamoutou health center laboratories of Lastourville, respectively. They are also grateful to the staff of the Unit of Evolution, Epidemiology and Parasitic Resistances at International Medical Research Center of Franceville (CIRMF), the Parasitology and Entomology Unit of Biomedical Research Institute of Army, and the National Malaria Reference Center of Marseille.

**Author contributions**

All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


